Key result
Low-molecular-weight heparin during anticancer therapy is hypothesized to have a direct antitumor effect that may translate into a survival benefit for patients with cancer.
Key points are not available for this paper at this time.
Direct antitumor effect of LMWH in cancer remains hypothetical; leaves open any survival benefit.
To the editor: The use of low-molecular-weight heparin (LMWH) during anticancer therapy has been studied by several authors, who speculated about a direct antitumor effect of LMWH, which might be translated into a survival benefit in patients with cancer.[1][1] Other authors have suggested that the
No takes yet. Share an insight, caveat, or question.
Barni et al. (2014) studied this question. Low-molecular-weight heparin during anticancer therapy is hypothesized to have a direct antitumor effect that may translate into a survival benefit for patients with cancer.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: